Kyverna Therapeutics (KYTX) Retained Earnings (2023 - 2026)
Kyverna Therapeutics posted quarterly Retained Earnings of -$464.6 million for Q1 2026, down 46459900.0% year-on-year from N/an in Q1 2025, and down 9.36% on a QoQ basis from -$424.8 million in Q4 2025.
Kyverna Therapeutics (KYTX) has 4 years of Retained Earnings data on file, last reported at -$464.6 million in Q1 2026.
- For the quarter ending Q1 2026, Retained Earnings fell 46459900.0% year-over-year to -$464.6 million; the trailing twelve-month figure through Mar 2026 stood at -$464.6 million (down 46459900.0% YoY), and the FY2025 full-year result was -$424.8 million, down 404697.14% from the prior year.
- Retained Earnings for Q1 2026 stood at -$464.6 million, down from -$424.8 million in the prior quarter.
- Across five years, Retained Earnings topped out at $105000.0 in Q4 2024 and bottomed at -$464.6 million in Q1 2026.
- The 4-year median for Retained Earnings is -$68.0 million (2023), against an average of -$144.3 million.
- The widest annual swing landed in 2024, when Retained Earnings surged 100.08%; it then tumbled 46459900.0% in 2026.
- A 4-year view of Retained Earnings shows it stood at -$136.0 million in 2023, then surged by 100.08% to $105000.0 in 2024, then slumped by 404697.14% to -$424.8 million in 2025, then fell by 9.36% to -$464.6 million in 2026.
- The last three Retained Earnings figures came in at -$464.6 million (Q1 2026), -$424.8 million (Q4 2025), and $29000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Kyverna Therapeutics | 497.98 Mn | 265.03 Mn | - | -464.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -464.60 Mn |
| Dec 31, 2025 | -424.83 Mn |
| Sep 30, 2025 | 29,000.00 |
| Jun 30, 2025 | -20,000.00 |
| Mar 31, 2025 | -1,000.00 |
| Dec 31, 2024 | 105,000.00 |
| Sep 30, 2024 | -226.00 Mn |
| Jun 30, 2024 | -191.54 Mn |
| Mar 31, 2024 | -1,000.00 |
| Dec 31, 2023 | -136.04 Mn |